Colin Hislop

Dr. Hislop has over 34 years of experience in drug development including small molecules, peptides, and biologics, across therapeutic areas in both large pharma and start-up companies. Prior to joining Eiger full-time, Dr. Hislop was the Company’s senior medical advisor to the Progeria program and was instrumental to Eiger’s first NDA submission of Lonafarnib for the treatment of Progeria and Progeroid Laminopathies. Prior to joining Eiger, Dr. Hislop served as Chief Medical Officer at Versartis and Anthera. He was previously Vice President and Head of Clinical Development at Peninsula Pharmaceuticals developing doripenem for systemic infections. Peninsula was acquired by J&J for $245 million. Dr. Hislop served as Vice President of Clinical Development at CV Therapeutics where he developed and filed an NDA for Ranexa® for angina. CV Therapeutics was acquired by Gilead for $1.4 billion. He previously led the development of Actonel® through initial FDA approvals for osteoporosis at Proctor & Gamble. Dr. Hislop began his industry career at Eli Lilly as Medical Director of Endocrinology for insulin and growth hormone. During his career, Dr. Hislop has been involved in all phases of drug development from IND to Phase 4 and has led numerous US, European, and global regulatory filings, including 4 NDAs.

Dr. Hislop earned a Bachelor of Science in Medical Biochemistry from the University of Surrey and a Bachelor of Medicine, and a Bachelor of Surgery (M.B.B.S.) at the University of London.